David M. O’Malley

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum”.

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Journal of Clinical Oncology(2020)10.1200/jco.20.01164

N/A

4.6DataRank · unranked

153 citations

Rachel N. Grisham, Susana Banerjee, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero +25 more

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.04.012

N/A

1.3DataRank · unranked

36 citations

José Alejandro Pérez Fidalgo, Bradley J. Monk, Ignacio Tusquets, Colleen McCormick, José Fuentes +20 more

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0621

N/A

0.949DataRank · unranked

22 citations

Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza +25 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

International Journal of Gynecological Cancer(2024)10.1136/ijgc-2024-005919

N/A

0.812DataRank · unranked

25 citations

Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Michel Fabbro, David M. O’Malley +16 more

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Journal of Clinical Oncology(2025)10.1200/jco-25-00112

N/A

0.722DataRank · unranked

36 citations

Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley J. Monk, Andrew R. Clamp +20 more

Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279

Journal of Clinical Oncology(2024)10.1200/jco.23.02235

N/A

0.637DataRank · unranked

19 citations

Wei Deng, I. Peterson, Robert S. Mannel, J. S. Thompson, Elizabeth Lokich +12 more

High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.101040

N/A

0DataRank · unranked

7 citations

David A. Mix Barrington, Morgan Brown, Lynette Gonzalez, Jae Suk Baek, Allison Huffman +10 more

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial

Nature Communications(2025)10.1038/s41467-024-55200-2

N/A

0DataRank · unranked

18 citations

Dmitriy Zamarin, Wei Deng, Heather A. Lankes, Giulio Pesci, Hayeon Kim +19 more

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-3042

N/A

0DataRank · unranked

2 citations

Austin Miller, Heather A. Lankes, Kwong‐Kwok Wong, William H. Rodgers, David Millan +20 more

Assessment of readability of gynecologic cancer clinical trials literature at National Cancer Institute–designated Comprehensive Cancer Centers

International Journal of Gynecological Cancer(2025)10.1016/j.ijgc.2025.101693

N/A

0DataRank · unranked

1 citations

Wafa Khadraoui, John L. Hays, Larry J. Copeland, Roberto Vargas, David M. O’Malley +2 more

Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinoma

Gynecologic Oncology Reports(2025)10.1016/j.gore.2025.101782

N/A

0DataRank · unranked

0 citations

Molly Morton, Eric McLaughlin, Anna Gonzalez, Jessica Fulton, Jessica Sciuva +11 more

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-0226

N/A

0DataRank · unranked

57 citations

Kirsten B. Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu +16 more

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials

UNC Libraries(2020)10.17615/2xde-se42

N/A

0DataRank · unranked

0 citations

Phuong L. Mai, David S. Alberts, William J. Welch, Carol J. Fabian, Mary B. Daly +32 more

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab

The Oncologist(2021)10.1002/onco.13883

N/A

0DataRank · unranked

34 citations

Matthew H. Taylor, Ana Oaknin, Antonio Casado, Robert Orlowski, Lea Dutta +4 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.08.021

N/A

0DataRank · unranked

57 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +17 more